` 1099 (Sinopharm Group Co Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

1099
vs
Hang Seng (Hong Kong)

Over the past 12 months, has underperformed Hang Seng (Hong Kong), delivering a return of -4% compared to the Hang Seng (Hong Kong)'s 17% growth.

Stocks Performance
1099 vs Hang Seng (Hong Kong)

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
1099 vs Hang Seng (Hong Kong)

Loading
1099
Hang Seng (Hong Kong)
Difference

Performance By Year
1099 vs Hang Seng (Hong Kong)

Loading
1099
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Sinopharm Group Co Ltd vs Peers

Hang Seng (Hong Kong)
1099
MCK
COR
0HF3
CAH
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Sinopharm Group Co Ltd
Glance View

Market Cap
62.4B HKD
Industry
Health Care

Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.

Intrinsic Value
78.18 HKD
Undervaluation 74%
Intrinsic Value
Price
Back to Top